The Filing Desk

Myriad Genetics vs Pennant Group

Myriad Genetics MYGN · Pennant Group PNTG · Health Care Services

Pennant Group reported revenue of $948 million in fiscal 2025, about the same as Myriad Genetics' $824 million in fiscal 2025. Myriad Genetics' revenue fell 1.6% in its latest year, and Pennant Group's grew 36.3%. Myriad Genetics had an operating margin of -47.0%, against 5.5% at Pennant Group. Free cash flow was −$14 million at Myriad Genetics and $36 million at Pennant Group.

Side by side

Myriad GeneticsPennant Group
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$824M$948M
Revenue growth−1.6%36.3%
Revenue growth a year, last 5 years5.2%19.4%
Gross margin69.9%—
Operating margin−47.0%5.5%
Net margin−44.4%3.1%
Free cash flow−$14M$36M
Free cash flow margin−1.7%3.8%
Return on capital−62.6%9.3%
Net debt to EBITDA—2.6x
Dividends and buybacks$0M$0M
Change in diluted share count2.2%10.4%
Last close$5.66$36.07
P/E at the last close—36.1×
Insider trades, last 12 months—sold $690,087
Piotroski F-score5 of 95 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Myriad GeneticsPennant Group
Operating margin
Percent of revenue
Myriad GeneticsPennant Group
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Myriad GeneticsPennant Group

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Myriad Genetics and Pennant Group pages.